The Symptomatic Effect of Cisapride in Patients with Irritable Bowel Syndrome and Constipation
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Cisapride improves symptoms in patients with idiopathic constipation. This trial compares the effect of cisapride with that of placebo in patients with irritable bowel syndrome (IBS) and constipation. METHODS: Seventy patients were randomized to 12 weeks' treatment with 5 mg cisapride three times daily or placebo in a double-blind trial. The dose could be doubled after 4 weeks in patients without satisfactory improvement. The patients scored their symptoms on a 100-mm visual analogue scale (VAS) (0 = best, 100 = worst), and the investigators evaluated the symptomatic effect. RESULTS: The dose was doubled in 17 and 23 patients in the cisapride and placebo groups, respectively, after 4 weeks. The patients' mean VAS score for global evaluation of IBS symptoms in the cisapride and placebo groups was 73 and 71 mm, respectively, at the start of treatment and 47 and 41 mm at the end. The difference between cisapride and placebo at the end was 6 mm in favour of placebo (95% confidence interval (CI), -6, 18) (NS). The investigators evaluated the effect as good or excellent in 39.2% and 58.8% in the cisapride and placebo groups, respectively. The difference in favour of placebo was 19.5% (95% CI, -5, 44) (NS). Nor were any statistically significant differences seen between cisapride and placebo in the other effect factors. CONCLUSIONS: The trial seems to exclude a clinically significant effect of 15-30 mg cisapride daily in patients with IBS and constipation during a 12-week treatment period.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drossman, D. A., Li, Z., Andruzzi, E., Temple, R. D., Talley, N. J., Grant Thompson, W., Whitehead, W. E., Janssens, J., Funch-Jensen, P., Corazziari, E., et al. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01303162 · Cited by 2,198
Cited by
Ford, A. C., Moayyedi, P., Lacy, B. E., Lembo, A. J., Saito, Y. A., Schiller, L. R., Soffer, E. E., Spiegel, B. M. R., & Quigley, E. M. M. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.187 · Cited by 645
Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis
Jackson, J. L., O’Malley, P. G., Tomkins, G., Balden, E., Santoro, J., & Kroenke, K. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00299-5 · Cited by 469
Jailwala, J., Imperiale, T. F., & Kroenke, K. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-2-200007180-00013 · Cited by 381
Role of serotonin in the pathophysiology of the irritable bowel syndrome
Crowell, M. D. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705762 · Cited by 291
The placebo effect in irritable bowel syndrome trials: a meta‐analysis1
Patel, S. M., Stason, W. B., Legedza, A., Ock, S. M., Kaptchuk, T. J., Conboy, L., Canenguez, K., Park, J. K., Kelly, E., Jacobson, E., et al. (2005) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2005.00650.x · Cited by 285
Metadata
- Authors
- P. G. FARUP, N. H.
- Venue
- Scandinavian Journal of Gastroenterology
- Publisher
- Informa UK Limited
- Published
- 1998-01
- Volume
- 33
- Issue
- 2
- Pages
- 128-131
- ISSN
- 0036-5521 (ISSN-L)
- 1502-7708
- OpenAlex
- W2162620255
- Cited by
- 51
- References
- 1
- FWCI
- 6.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Symptomatic Effect of Cisapride in Patients with Irritable Bowel Syndrome and Constipation. https://app.cochat.ai/papers/10.1080/00365529850166833
- The paper
- P. G. FARUP, N. H. (1998). The Symptomatic Effect of Cisapride in Patients with Irritable Bowel Syndrome and Constipation. Scandinavian Journal of Gastroenterology. https://doi.org/10.1080/00365529850166833
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.